Edition:
United Kingdom

Vanda Pharmaceuticals Inc (VNDA.OQ)

VNDA.OQ on NASDAQ Stock Exchange Global Market

14.55USD
25 Apr 2018
Change (% chg)

$-0.05 (-0.34%)
Prev Close
$14.60
Open
$14.55
Day's High
$14.75
Day's Low
$14.40
Volume
66,831
Avg. Vol
164,460
52-wk High
$20.35
52-wk Low
$11.90

Chart for

About

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment... (more)

Overall

Beta: 1.10
Market Cap(Mil.): $766.38
Shares Outstanding(Mil.): 51.26
Dividend: --
Yield (%): --

Financials

  VNDA.OQ Industry Sector
P/E (TTM): -- 178.44 32.31
EPS (TTM): -0.35 -- --
ROI: -10.55 -0.73 12.97
ROE: -11.85 -2.77 14.84

BRIEF-Vanda Pharmaceuticals Wins Appeal Case On Fanapt

* U.S. FEDERAL COURT AFFIRMED U.S. COURT'S DECISION THAT WEST WARD PHARMACEUTICALS INFRINGED CO'S U.S. '610 PATENT FOR FANAPT

13 Apr 2018

BRIEF-Vanda Pharmaceuticals Gets Paragraph IV Certification Notice For Generic Version Of Hetlioz Capsule

* VANDA PHARMACEUTICALS - ON MARCH 23, GOT PARAGRAPH IV CERTIFICATION NOTICE LETTER REGARDING ANDA BY TEVA FOR GENERIC VERSION OF 20MG HETLIOZ CAPSULE

26 Mar 2018

BRIEF-Vanda Pharma Prices Public Offering Of Common Stock

* ‍SALE OF 5.5 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING AT $17.00 PER SHARE​ Source text for Eikon: Further company coverage:

16 Mar 2018

BRIEF-Vanda Pharmaceuticals Inc. Proposes Public Offering Of Common Stock

* VANDA PHARMACEUTICALS INC. PROPOSES PUBLIC OFFERING OF COMMON STOCK

14 Mar 2018

BRIEF-Vanda's Hetlioz Demonstrates Efficacy To Treat Jet Lag Disorder

* HETLIOZ® (TASIMELTEON) DEMONSTRATES EFFICACY TO TREAT JET LAG DISORDER IN AN 8 HOUR PHASE ADVANCE CLINICAL STUDY

05 Mar 2018

BRIEF-Vanda Pharmaceuticals Qtrly Net Loss Per Share $0.04

* VANDA PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 AND FULL YEAR 2017 FINANCIAL RESULTS

14 Feb 2018

BRIEF-Vanda receives negative opinion for marketing authorization from the European Medicines Agency

* Vanda receives negative opinion for marketing authorization from the European Medicines Agency on fanaptum™ for the treatment of schizophrenia

10 Nov 2017

BRIEF-Vanda Pharmaceuticals posts qtrly ‍net loss of $0.10​/share

* Qtrly ‍net loss per share $0.10​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

07 Nov 2017

Competitors

Earnings vs. Estimates